LINK Healthcare today announced it had been granted a licence to market Relistor® (methylnaltrexone) in Australia, New Zealand, South Africa and Asia from Salix Pharmaceuticals, Inc. of North Carolina, USA. Relistor subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to

GUARDIA (COMO), Italy, June 15, 2011, (GLOBE NEWSWIRE) — Gentium S.p.A.(NASDAQ: GENT) announced the appointment of LINK Pharmaceuticals as exclusive distributor of Defibrotide in Australia and New Zealand. Under the terms of the agreement, LINK will be responsible for managing named patient requests